Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL

NCT07120633 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

CLL
CAR-T Cell Therapy
SLL

Interventions

OTHER: AntiCD19 CAR-T combined with BTKi in the treatment of newly diagnosed high-risk CLL/SLL patients

Sponsor

The Affiliated Hospital of Xuzhou Medical University